{"id":"W2765867855","doi":"10.1111/cas.13427","title":"Everolimus in advanced, progressive, well‐differentiated, non‐functional neuroendocrine tumors: <scp>RADIANT</scp>‐4 lung subgroup analysis","year":2017,"lang":"en","type":"article","venue":"Cancer Science","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Everolimus; Medicine; Placebo; Clinical endpoint; Hazard ratio; Internal medicine; Gastroenterology; Adverse effect; Oncology; Subgroup analysis; Surgery; Confidence interval; Randomized controlled trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002262946,0.0008807296,0.003674458,0.0009207658,0.0001442644,0.0008880439,0.0003627467,0.0005578171,0.001847881],"category_scores_gemma":[0.00166604,0.0002562804,0.007859,0.0007948375,0.000160073,0.0002285777,0.0003836777,0.0006313397,0.0001981052],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005881374,"about_ca_system_score_gemma":0.0007043398,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00138692,"about_ca_topic_score_gemma":0.007766707,"domain_scores_codex":[0.9986621,0.0007379106,0.0002590821,0.0001245555,0.0001321436,0.00008427166],"domain_scores_gemma":[0.9992831,0.0003122809,0.0001931696,0.00006000099,0.00007818846,0.0000732586],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4689755,0.0005788004,0.02877651,0.03208112,0.3159018,0.0008436234,0.0002437812,0.003249906,0.0169937,0.0004971458,0.006579893,0.1252782],"study_design_scores_gemma":[0.2930981,0.02951013,0.1148598,0.002519309,0.5246407,0.001668329,0.0002894238,0.003393955,0.0073505,0.002004438,0.02053654,0.0001287819],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7515888,0.2335669,0.001351752,0.00100247,0.0004727247,0.001834677,0.005692789,0.0001165167,0.004373426],"genre_scores_gemma":[0.9704836,0.02329872,0.0008613087,0.0006227954,0.0002392934,0.0006014142,0.001882369,0.0000232607,0.001987219],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003674458,"threshold_uncertainty_score":0.01196778,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02009855395982761,"score_gpt":0.3434529611111763,"score_spread":0.3233544071513487,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}